Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.59 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299809 | 1.00 | LPL (0.59) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29644319 | 0.96 | LPL (0.62) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1293460 | 0.96 | LPL (0.62) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL13142480 | 0.94 | LPL (0.68) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29387132 | 0.94 | LPL (0.61) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1294059 | 0.94 | LPL (0.61) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL11959548 | 0.91 | LPL (0.51) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL120527 | 0.88 | LPL (0.75) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29392121 | 0.88 | LPL (0.75) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12654466 | 0.86 | LPL (0.54) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3002281-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-9139569-B2 | Fused tricyclic aryl compounds useful for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139569-B2 | Fused tricyclic aryl compounds useful for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2007117872-A2 | ELECTRONIC DEVICES CONTAINING ACENE-THIOPHENE COPOLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117872-A2 | ELECTRONIC DEVICES CONTAINING ACENE-THIOPHENE COPOLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007115021-A2 | ACENE-THIOPHENE COPOLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115021-A2 | ACENE-THIOPHENE COPOLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232781-A1 | ACENE-THIOPHENE COPOLYMERS | 3M INNOVATIVE PROPERTIES COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232781-A1 | ACENE-THIOPHENE COPOLYMERS | 3M INNOVATIVE PROPERTIES COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232781-A1 | ACENE-THIOPHENE COPOLYMERS | 3M INNOVATIVE PROPERTIES COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070228360-A1 | ELECTRONIC DEVICES CONTAINING ACENE-THIOPHENE COPOLYMERS | 3M INNOVATIVE PROPERTIES COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070228360-A1 | ELECTRONIC DEVICES CONTAINING ACENE-THIOPHENE COPOLYMERS | 3M INNOVATIVE PROPERTIES COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070228360-A1 | ELECTRONIC DEVICES CONTAINING ACENE-THIOPHENE COPOLYMERS | 3M INNOVATIVE PROPERTIES COMPANY | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | LPL 2383/4885LIPG 1280/4885CA1 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.